To the Editor Drs Kolodny and Frieden 1 outlined steps the government should take to curb the opioid epidemic, such as improving surveillance of prescribers through the use of databases, improving reporting and responses to overdoses, promoting more cautious guidelines for use of narcotics, increasing access and reimbursement for nonopioid and nonpharmacologic management of pain, interrupting supply of heroin and illicitly produced synthetic opioids, increasing access to addiction treatment, and reducing harm to current users. However, they left out the role the Drug Enforcement Administration (DEA) can play in its ability to block drug manufacturers and drug distributors from shipping suspiciously large narcotic shipments.Shipment seizure was hampered when the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 2 was signed into law. Designed to ensure patient access to prescription opioids for legitimate use, it also changed the criteria used to justify opioid shipment seizures when sheer numbers of pills ordered by pain clinics, physicians, and pharmacies made it likely that these agents were supplying prescription opioids for diversion onto the black market. The DEA previously had authority to seize shipments that imposed "imminent danger," but the law requires the DEA to demonstrate that a shipment would represent a "substantial likelihood of an immediate threat." 2 This legal bar is much higher and basically prevents the DEA from using immediate suspension orders in cases involving drug manufacturers and distributors. This law was lobbied for by pharmaceutical companies and drug distributors between 2014 and 2016. [3][4][5] Since its passage, immediate suspension orders against physicians, pharmacies, drug distributors, and drug companies have decreased. 3